IL-12 minicircle delivery via extracellular vesicles as immunotherapy for bladder cancer

Abstract

Interleukin-12 (IL-12) holds significant potential in cancer therapy; however, its clinical applicability is hindered by dose-limiting toxicity. Delivery of the IL-12 gene directly to tumours for constitutive IL-12 expression is a possible strategy to enhance its effectiveness while minimizing systemic toxicity. In this study, we investigate the potential of red blood cell-derived extracellular vesicles (RBCEVs) as a carrier for Il-12 plasmid delivery. We demonstrate that RBCEVs can be loaded with minicircle plasmid encoding IL-12 and delivered to MB49 bladder cancer cells for IL-12 expression. The expression of transgenes from minicircles was significantly higher than from the parental plasmids. RBCEV-mediated IL-12 expression stimulated immune responses in mouse splenocytes. Intratumoral delivery of Il-12 plasmid-loaded RBCEVs suppressed bladder cancer tumour growth, stimulated immune responses and promoted immune cell infiltration. In conclusion, our study demonstrates the promising potential of RBCEVs as an effective, safe and redosable nucleic acid drug delivery platform for IL-12.

References

[1] ZhangY, ZhangZ. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807-821.

[2] Del VecchioM, Bajetta E, CanovaS, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13(16):4677-4685.

[3] NguyenKG, VrabelMR, MantoothSM, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol. 2020;11:575597.

[4] TuguesS, Burkhard SH, OhsI, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22(2):237-246.

[5] AtkinsMB, Robertson MJ, GordonM, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3(3):409-417.

[6] LeonardJP, Sherman ML, FisherGL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541-2548.

[7] StraussJ, Deville JL, SznolM, et al. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. J Immunother Cancer. 2023;11(5):e005813.

[8] WangP, LiX, WangJ, et al. Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017;8(1):1395.

[9] WangC, PanC, YongH, et al. Emerging non-viral vectors for gene delivery. J Nanobiotechnol. 2023;21(1):272.

[10] CirellaA, Luri-Rey C, di TraniCA, et al. Novel strategies exploiting interleukin-12 in cancer immunotherapy. Pharmacol Ther. 2022;239:108189.

[11] LeeY, JeongM, ParkJ, Jung H, LeeH. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med. 2023;55(10):2085-2096.

[12] UsmanWM, PhamTC, KwokYY, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9(1):2359.

[13] ChenH, Jayasinghe MK, YeoEYM, et al. CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and miR-125b for specific treatment of acute myeloid leukaemia. Cell Prolif. 2022;55(9):e13255.

[14] JayasingheMK, GaoC, YapG, et al. Red blood cell-derived extracellular vesicles display endogenous antiviral effects and enhance the efficacy of antiviral oligonucleotide therapy. ACS Nano. 2023;17(21):21639-21661.

[15] PengB, YangY, WuZ, et al. Red blood cell extracellular vesicles deliver therapeutic siRNAs to skeletal muscles for treatment of cancer cachexia. Mol Ther. 2023;31(5):1418-1436.

[16] SiegelRL, Giaquinto AN, JemalA. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.

[17] LammDL. Bladder cancer: twenty years of progress and the challenges that remain. CA Cancer J Clin. 1998;48(5):263-268.

[18] JeongS-H, KuJH. Treatment strategies for the bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. Investig Clin Urol. 2023;64(2):103-106.

[19] PhamTC, Jayasinghe MK, PhamTT, et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracell Vesicles. 2021;10(4):e12057.

[20] VanrellL, di Scala M, BlancoL, et al. Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther. 2011;19(7):1245-1253.

[21] ZaharoffDA, Hoffman BS, HooperHB, et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res. 2009;69(15):6192-6199.

[22] DanhierF, FeronO, PréatV. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-146.

[23] YangJ, ShayC, SabaNF, Teng Y. Cancer metabolism and carcinogenesis. Exp Hematol Oncol. 2024;13(1):10.

[24] BaiH, LesterGMS, PetishnokLC, Dean DA. Cytoplasmic transport and nuclear import of plasmid DNA. Biosci Rep. 2017;37(6):BSR20160616.

[25] BrunnerS, SauerT, CarottaS, Cotten M, SaltikM, WagnerE. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther. 2000;7(5):401-407.

[26] GrosseS, Thévenot G, MonsignyM, FajacI. Which mechanism for nuclear import of plasmid DNA complexed with polyethylenimine derivatives? J Gene Med. 2006;8(7):845-851.

[27] ŠimčíkováM, PratherKLJ, Prazeres DMF, MonteiroGA. Towards effective non-viral gene delivery vector. Biotechnol Genet Eng Rev. 2015;31(1-2):82-107.

[28] PalmiterRD, Sandgren EP, AvarbockMR, AllenDD, Brinster RL. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA. 1991;88(2):478-482.

[29] DeanDA, DeanBS, MullerS, Smith LC. Sequence requirements for plasmid nuclear import. Exp Cell Res. 1999;253(2):713-722.

[30] BrunS, Faucon-Biguet N, MalletJ. Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy. Mol Ther. 2003;7(6):782-789.

[31] SalemTZ, Seaborn CP, TurneyCM, XueJ, ShangH, ChengXW. The influence of SV40 polyA on gene expression of baculovirus expression vector systems. PLoS One. 2015;10(12):e0145019.

[32] GollobJA, MierJW, VeenstraK, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res. 2000;6(5):1678-1692.

[33] TsaiYS, ShiauAL, ChenYF, Tsai HT, TzaiTS, WuCL. Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy. Cancer Gene Ther. 2010;17(1):37-48.

[34] ChoiJ-N, SunEG, ChoS-H. IL-12 enhances immune response by modulation of myeloid derived suppressor cells in tumor microenvironment. Chonnam Med J. 2019;55(1):31-39.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.